Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 10/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4260396 | 0.89 | MMP13 (0.53) | MMP13SMN1; SMN2NPC1RAB9AHDAC6 | |
| SCHEMBL4261846 | 0.87 | SMN1; SMN2 (0.53) | MMP13SMN1; SMN2NPC1RAB9AHDAC6 | |
| SCHEMBL4259918 | 0.85 | SMN1; SMN2 (0.53) | MMP13SMN1; SMN2NPC1RAB9AHDAC6 | |
| SCHEMBL4256553 | 0.85 | MMP13 (0.54) | MMP13CYP19A1TBXAS1LMNA | |
| SCHEMBL4262326 | 0.83 | SMN1; SMN2 (0.66) | MMP13SMN1; SMN2NPC1RAB9AHDAC6 | |
| SCHEMBL4256694 | 0.82 | SMN1; SMN2 (0.68) | MMP13SMN1; SMN2NPC1RAB9AHDAC6 | |
| SCHEMBL4262801 | 0.80 | SMN1; SMN2 (0.56) | MMP13SMN1; SMN2NPC1RAB9AHDAC6 | |
| SCHEMBL4263428 | 0.80 | SMN1; SMN2 (0.56) | MMP13SMN1; SMN2NPC1RAB9AHDAC6 | |
| SCHEMBL4254996 | 0.80 | SMN1; SMN2 (0.62) | MMP13SMN1; SMN2NPC1RAB9AHDAC6 | |
| SCHEMBL4263454 | 0.76 | MMP13 (0.54) | MMP13SMN1; SMN2NPC1RAB9AHDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090029995-A1 | HETERO BIARYL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2009-01-29 | — | — | US | disclosed |
| US-20090029995-A1 | HETERO BIARYL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2009-01-29 | — | — | US | disclosed |
| US-20090029995-A1 | HETERO BIARYL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2009-01-29 | — | — | US | disclosed |
| US-7179822-B2 | Hetero biaryl derivatives as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2007-02-20 | — | — | US | disclosed |
| US-7179822-B2 | Hetero biaryl derivatives as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2007-02-20 | — | — | US | disclosed |
| US-20040048863-A1 | Hetero biaryl derivatives as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY LLC | 2004-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029995-A1 | HETERO BIARYL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | MMP9, MMP2, MMP3 | MMP13 8/4885SMN1; SMN2 2194/4885NPC1 1536/4885 |
| US-20040048863-A1 | Hetero biaryl derivatives as matrix metalloproteinase inhibitors | MMP13, MMP11, MMP9 | MMP13 1/4885SMN1; SMN2 1617/4885NPC1 1391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.